对于临床病理因素预测一致结果的术前可能性非常高的浸润性乳腺癌患者，可否省略 Oncotype DX 检测？
Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result?
机构信息
Department of Surgery, Harbor-UCLA Medical Center, Torrance, CA, USA.
Department of Pathology, Harbor-UCLA Medical Center, Torrance, CA, USA.
出版信息
Breast J. 2020 Nov;26(11):2199-2202. doi: 10.1111/tbj.14068. Epub 2020 Oct 1.
OBJECTIVE
To determine if clinicopathologic (CP) factors could identify patients at "very low" and/or "very high" pretest probability of a high Oncotype DX (ODX) score.
METHODS
A retrospective analysis of all patients that had ODX testing 2008-2018 at a single institution.
RESULTS
Of 215 patients, all 16 (7.4%) with "all high" risk CP factors had high ODX scores, and all 45 (20.9%) over age 50 with "all low" risk CP factors had ODX recommendations for no chemotherapy.
CONCLUSIONS
Oncotype DX results did not change chemotherapy recommendations in those with "very low" or "very high" pretest probability of high ODX scores.
目的
确定临床病理（CP）因素是否可以识别出术前预测奥曲肽 DX（ODX）评分高的“极低”和/或“极高”患者。
方法
对 2008 年至 2018 年在一家机构接受 ODX 检测的所有患者进行回顾性分析。
结果
在 215 名患者中，所有 16 名（7.4%）具有“所有高危”CP 因素的患者 ODX 评分较高，所有 45 名（20.9%）年龄大于 50 岁且具有“所有低危”CP 因素的患者 ODX 建议不化疗。
结论
在术前预测 ODX 评分高的“极低”或“极高”患者中，ODX 结果并未改变化疗建议。
Zotero 插件